AZM Alizyme

 

TIDMAZM 
 
RNS Number : 0214R 
Alizyme PLC 
23 April 2009 
 

 
 
+----------------------------------------+-------------------------------------+ 
| For immediate release                  |                       23 April 2009 | 
+----------------------------------------+-------------------------------------+ 
 
 
 
 
ALIZYME PLC 
 
 
BOARD CHANGES 
 
 
Cambridge UK, 23 April 2009: Alizyme plc (LSE:AZM) announces that Sir Brian 
Richards has informed the Board that he intends to step down as Chairman and 
retire as a Director of Alizyme plc at the conclusion of the forthcoming Annual 
General Meeting, to be held on 24 July 2009. Sir Brian has been Chairman of 
Alizyme since its formation. 
 
 
Mr Alan Goodman joins the Board as a Non-Executive Director with immediate 
effect and it is intended that he will assume the role of Chairman at the 
conclusion of the forthcoming Annual General Meeting. 
 
 
Mr Goodman, aged 58, has founded or co-founded many biotechnology and healthcare 
companies over the last 25 years, including Agricultural Genetics Company, 
Medeva plc, Chiroscience Group plc, Acambis plc, Oxford BioMedica plc, CeNeS 
Pharmaceuticals plc, Core Group plc and Amura Limited. He was Chief Executive of 
Acambis plc, non-executive Chairman of Oxford BioMedica plc and is currently a 
member of the Supervisory Board of Paion AG and Chief Executive of Avlar 
BioVentures Limited and a director of a number of private companies. 
 
 
There are no other disclosures relating to Mr Goodman under Listing Rule LR 
9.6.13. 
 
 
 
 
Tim McCarthy (Chief Executive Officer) commented: 
 
 
"Sir Brian has provided invaluable guidance and advice as Chairman of Alizyme 
since its formation, for which I and the Company are immensely grateful. I want 
to thank him for his unstinting efforts and wise counsel over many years and 
wish him well for the future. I welcome Alan's appointment as a Non-Executive 
Director and believe his succession as Chairman will bring a wealth of 
experience to the Board and is an important step for Alizyme in pursuing its 
strategy to become a profitable, self-sustaining biopharmaceutical product 
development company." 
 
 
 
 
For further information, please contact: 
 
 
+------------------------------------+---------------------------------+ 
| ALIZYME PLC                        |      Tel: + 44 (0) 1223 896000  | 
| Tim McCarthy, Chief Executive      |                                 | 
| Officer                            |                                 | 
|                                    |                                 | 
+------------------------------------+---------------------------------+ 
| BUCHANAN COMMUNICATIONS            |     Tel: + 44 (0) 20 7466 5000  | 
| Lisa Baderoon                      |     Tel: + 44 (0) 7721 413496   | 
| Rebecca Skye Dietrich              |                                 | 
+------------------------------------+---------------------------------+ 
 
 
Further information on Alizyme can be found on the Company's website: 
www.alizyme.com 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOAIFFSISIIFFIA 
 

Alizyme (LSE:AZM)
Historical Stock Chart
From May 2024 to Jun 2024

Alizyme (LSE:AZM)
Historical Stock Chart
From Jun 2023 to Jun 2024